Evidence map›Paper›PMID 32775335›Full record

ArticleBiomedicine hub

Propelling Health Care into the Twenties.

Denis Horgan, Bettina Borisch, Etienne Richer, Chiara Bernini, Dipak Kalra, Mark Lawler, Gennaro Ciliberto, Hendrik Van Poppel, Angelo Paradiso, Peter Riegman and 9 more

Abstract readEditorial
In one paragraph

Article in Biomedicine hub. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Fighting Cancer around the World: A Framework for Action.Healthcare (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Denis HorganEuropean Alliance for Personalised Medicine, Brussels, Belgium.
Bettina BorischBioCampus, Institute of Global Health, University of Geneva, Geneva, Switzerland.
Etienne RicherCIHR Institute of Genetics, Ottawa, Ontario, Canada.
Chiara BerniniEuropean Alliance for Personalised Medicine, Brussels, Belgium.
Dipak KalraThe European Institute for Innovation through Health Data (i-HD), Gent, Belgium.
Mark LawlerQueen's University Belfast, Belfast, United Kingdom.
Gennaro CilibertoIRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.
Hendrik Van PoppelUZ Leuven, Leuven, Belgium.
Angelo ParadisoIstituto dei Tumori Giovanni Paolo II, Bari, Italy.
Peter RiegmanErasmus MC, Rotterdam, The Netherlands.
Stefano TribertiDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Andres MetspaluEstonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
Arturo ChitiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Elizabeth MacintyreLaboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Stefania BocciaSezione di Igiene, Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italy.
Fabien CalvoCancerCore Europe, Paris, France.
Desmond SchatzDepartment of Pediatrics, University of Florida, Gainesville, Florida, USA.
Jasmina Koeva-BalabanovaBulgarian Alliance for Personalised and Precision Medicine, Sofia, Bulgaria.
Bengt JonssonStockholm School of Economics (SSE), Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The scope and potential of personalised health care are underappreciated and underrealised, often because of resistance to change. The consequence is that many inadequacies of health care in Europe persist unnecessarily, and many opportunities for improvement are neglected. This article identifies the principal challenges, outlines possible approaches to resolving them, and highlights the benefits that could result from greater adoption of personalised health care. It locates the discussion in the context of European policy, focusing particularly on the most recent and authoritative reviews of health care in the EU Member States, and on the newly acquired spirit of readiness and pragmatism among European officials to embrace change and innovative technologies in a new decade. It highlights the attention now being given by policymakers to incentives, innovation, and investment as levers to improve European citizens' prospects in a rapidly evolving world, and how these distinct and disruptive themes contribute to a renaissance in thinking about delivering optimal health care in Europe. It explores the chances offered to patients by specific initiatives in health domains such as cancer and antimicrobial resistance, and by innovative science, novel therapies, earlier diagnosis tools, and deeper understanding of health promotion and prevention. And it reflects on how health care providers could benefit from a shift towards better primary care and towards deploying health data more effectively, including the use of artificial intelligence, coupled with a move to a smoother organisational/regulatory structure and realigned professional responsibilities. The conclusion is that preparing Europe's health care systems for the inevitable strains of the coming years is both possible and necessary. A more courageous approach to embracing personalised health care could guarantee the sustainability of Europe's health care systems before rising demands and exponential costs overwhelm them - an exercise in future-proofing, in ensuring that they are equipped to withstand whatever lies ahead. A focus on the potential and implementation of personalised care would permit more efficient use of resources and deliver better quality health-preserving care.

Indexed as

AccessBiomarkers, optimalCitizensData-translational researchDiagnosticsEmpowerment patientEuropean CommissionFrameworksHealth economicsHealth policy, regulatoryIncentivesInnovationMember statesPersonalised health carePersonalised medicinePharmacoeconomicsPrecision medicinePreventive medicinePublic healthReal-world dataReimbursement

Identifiers

PMID32775335
PMCPMC7392387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.